Our experienced international advisors help make deals successful. They can navigate the risks and barriers which range from dealing with different business ethics to unfamiliar legal systems. With the correct advice, international deals can offer improved returns from economies of scale, new target markets for existing products and services, access to commodity materials, and a hedge against seasonality.
Crowe advises 1Q Health on the cross-border acquisition of a majority stake in the EHF Group
EHF (located in the Netherlands) draws on more than 25 years of experience in developing and manufacturing dietary supplements. Its newly occupied, state-of-the-art production site in Capelle aan den Ijssel, opened in 2024, provides ample space for further growth and expansion. At this site, the EHF team produces high-quality powders, tablets, and hard capsules under IFS-certified conditions.
1Q Health (headquartered in Germany) is a leading European CDMO and development partner for dietary supplements and pharmaceuticals. The company focuses on supporting dynamic clients throughout the entire product lifecycle and beyond—from development and production to logistics and regulatory support. At its state-of-the-art production facilities in Germany, Austria, and now also the Netherlands, 1Q Health manufactures hard capsules, liquids, powders, and tablets under GMP and IFS/FSSC conditions. In addition, 1Q Health supports clients in their international market expansion and online presence.
As the first member outside the DACH region, EHF expands the production capacity and expertise of the 1Q Health Group. Furthermore, EHF’s online formulator underscores the digital capabilities and service-oriented approach of the 1Q Health Group.
Crowe advises 1QHealth, a portfolio company of NORD Holding, in this cross-border transaction.
The financial and tax advisory support for the transaction was provided by an interdisciplinary Crowe team composed of Crowe BPG (Crowe Germany) and Crowe Foederer (Crowe Netherlands).